[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591144":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":105,"collaborators":7,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":109,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":121,"studyType":122,"phases":7,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Lexeo Therapeutics","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Lexeo Clinical Trials","STUDY_DIRECTOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Person*: Lexeo Clinical Trials","CONTACT","212-547-9879","clinicaltrials@lexeotx.com",[19,38,53,65,80,92],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Leland Stanford Junior University","RECRUITING","Redwood City","California","94063-3126","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-122.23635,37.48522,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":36,"phoneExt":7,"email":37},"Priya Nair","512-217-3812","ashas@stanford.edu",{"facility":39,"status":21,"city":40,"state":41,"zip":42,"country":25,"countryCode":26,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Johns Hopkins University","Baltimore","Maryland","21287",{"type":28,"coordinates":44},[45,46],-76.61219,39.29038,{"lat":46,"lon":45},[49],{"name":50,"role":15,"phone":51,"phoneExt":7,"email":52},"Crystal Tichnell","410-502-7161","ctichne1@jhmi.edu",{"facility":54,"status":21,"city":55,"state":41,"zip":56,"country":25,"countryCode":26,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Northshore University Healthsystem Research Institute","Columbia","21044",{"type":28,"coordinates":58},[59,60],-76.83942,39.24038,{"lat":60,"lon":59},[63],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":64},"bprindeville@northshore.org",{"facility":66,"status":21,"city":67,"state":68,"zip":69,"country":25,"countryCode":26,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University of Michigan","Ann Arbor","Michigan","48109",{"type":28,"coordinates":71},[72,73],-83.74088,42.27756,{"lat":73,"lon":72},[76],{"name":77,"role":15,"phone":78,"phoneExt":7,"email":79},"Muhammad Hussain","734-765-8217","muhammhu@med.umich.edu",{"facility":81,"status":21,"city":82,"state":68,"zip":83,"country":25,"countryCode":26,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Henry Ford Hospital","Detroit","48202",{"type":28,"coordinates":85},[86,87],-83.04575,42.33143,{"lat":87,"lon":86},[90],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":91},"wcabral1@hfhs.org",{"facility":93,"status":21,"city":94,"state":95,"zip":96,"country":25,"countryCode":26,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"University of Rochester","Rochester","New York","14642",{"type":28,"coordinates":98},[99,100],-77.61556,43.15478,{"lat":100,"lon":99},[103],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":104},"lori_caufield@urmc.rochester.edu",{"type":106,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100591144","a-study-to-assess-real-world-patient-characteristics-and-clinical-course-for-symptomatic-patients-with-pkp2-acm-100591144",false,"NCT06976606","A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM","An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)","SNAPSHOT- PKP2","Inclusion Criteria:\n\n* Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)\n* Documentation of a pathogenic or likely pathogenic truncating variant in PKP2\n* Frequent premature ventricular contractions (PVCs)\n* Patients must have an ICD placed prior to enrollment\n* Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.\n\nExclusion Criteria:\n\n* Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.\n* A history of other cardiac abnormalities as specified in the protocol.\n* New York Heart Association symptoms of heart failure of Class IV at the time of consent.\n* A history of prior gene transfer therapy.","ALL","18 Years","65 Years",{"count":119,"type":120},40,"ESTIMATED","1 Year","OBSERVATIONAL","An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.",[125,126,127],"Arrhythmogenic Cardiomyopathy","PKP2-ACM","PKP2-ARVC",[125,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143],"ACM","Cardiomyopathy","ARVC","Arrhythmogenic Right Ventricular","Arrhythmogenic Right Ventricular Dysplasia","Genetic cardiomyopathy","Gene Therapy","PKP2 Gene","Plakophilin-2","LX2020","SNAPSHOT-PKP2","Ventricular Arrhythmia","PVCs","Sudden Cardiac Death","Cardiac Arrest","2025-05-13",{"date":146,"type":147},"2025-05-16","ACTUAL",{"date":149,"type":147},"2024-01-23",{"date":151,"type":120},"2027-09",{"name":5,"class":6},6]